GlassScriptPhysician profile
Janice A Carr
NPI 1235302068
$6,210.19
in general payments reported to CMS, 2019-2025
56 companies · $1,224 in 2025
The $1,224 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,073 · 2022: $1,377 · 2023: $1,150 · 2024: $1,386 · 2025: $1,224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,576 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,576.47 |
| Education | $183.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $790.94 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Novartis Pharmaceuticals Corporation | $671.72 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $387.88 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Abbvie INC. | $329.81 | 2021-2025 | |
| Eisai INC. | $287.80 | 2021-2024 | |
| Janssen Biotech, INC. | $281.40 | 2021-2025 | Rybrevant, Carvykti, Darzalex |
| Incyte Corporation | $260.86 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Glaxosmithkline, LLC. | $223.38 | 2021-2025 | Ojjaara, Shingrix |
| Genzyme Corporation | $219.17 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $213.62 | 2021-2025 | |
| Seagen INC. | $197.75 | 2021-2023 | Adcetris |
| Astellas Pharma US INC | $177.95 | 2021-2024 | Padcev |
| Taiho Oncology, INC. | $173.54 | 2022-2025 | |
| Gilead Sciences, INC. | $160.09 | 2022-2025 | Trodelvy |
| Amgen INC. | $145.45 | 2021-2023 | Nplate, Vectibix, Kyprolis |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $136.38 | 2022-2025 | |
| Pharmacosmos Therapeutics INC. | $109.04 | 2022-2024 | Monoferric, Cosela |
| Celgene Corporation | $108.15 | 2021-2025 | Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $102.13 | 2022-2025 | Ninlaro, Vpriv, Alunbrig |
| Karyopharm Therapeutics INC. | $90.73 | 2023-2025 | Xpovio |
| E.R. Squibb & Sons, L.L.C. | $74.27 | 2021-2025 | Opdivo, Krazati |
| Pfizer INC. | $60.69 | 2023-2025 | |
| Emd Serono, INC. | $59.61 | 2021-2024 | Bavencio |
| Pharmacyclics LLC, An Abbvie Company | $58.28 | 2021-2023 | Imbruvica |
| Acrotech Biopharma INC. | $55.93 | 2021-2024 | Beleodaq |
| Kyowa Kirin, INC. | $48.09 | 2022-2024 | Poteligeo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.85 | 2021 | |
| Deciphera Pharmaceuticals INC. | $44.58 | 2021-2025 | Qinlock, Romvimza |
| Myriad Genetic Laboratories, INC. | $42.87 | 2024 | Myrisk |
| Astrazeneca Pharmaceuticals LP | $41.92 | 2021-2023 | |
| Genmab U.S., INC. | $38.76 | 2023-2025 | Epkinly |
| Pharmaessentia USA Corporation | $36.91 | 2025 | Besremi |
| Genentech USA, INC. | $36.24 | 2021-2024 | Tecentriq, Alecensa |
| Regeneron Healthcare Solutions, INC. | $34.75 | 2022-2024 | Libtayo |
| G1 Therapeutics, INC. | $33.46 | 2022 | |
| Coherus Oncology, INC. | $31.21 | 2021-2024 | |
| Epizyme, INC. | $30.67 | 2021-2022 | |
| Lilly USA, LLC | $29.03 | 2022-2023 | Verzenio, Jaypirca |
| Beigene USA, INC. | $26.23 | 2022 | |
| Jazz Pharmaceuticals INC. | $24.69 | 2021 | |
| Cti Biopharma Corp. | $23.35 | 2022 | |
| Aveo Pharmaceuticals, INC. | $23.14 | 2022 | |
| Alexion Pharmaceuticals, INC. | $19.72 | 2025 | Ultomiris |
| Beone Medicines USA, INC. | $19.50 | 2025 | Brukinsa |
| Dendreon Pharmaceuticals LLC | $18.93 | 2022 | |
| Sobi, INC | $18.89 | 2024 | |
| Apellis Pharmaceuticals, INC. | $18.24 | 2023 | Empaveli |
| Tempus Ai, INC | $18.16 | 2024 | Xt Cdx |
| Legend Biotech USA INC. | $17.82 | 2025 | Carvykti |
| Invivyd INC | $17.65 | 2025 | Pemgarda |
| Recordati_rare_diseases_inc. | $16.92 | 2023 | Sylvant |
| Array Biopharma INC | $16.04 | 2025 | Braftovi, Lorbrena, Mektovi |
| Octapharma USA, INC. | $15.13 | 2024 | Octagam Immune Globulin (Human) |
| Morphosys, US INC. | $14.97 | 2022 | |
| Myovant Sciences INC. | $14.92 | 2022 | |
| Agios Pharmaceuticals, INC. | $13.98 | 2023 | Pyrukynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janice Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.